Protein profiling of pleural effusions to identify XXXX using @entity66 .

@entity1 @entity4166 @entity66 @entity3422 @entity2615 @entity3620 @entity1096 @entity45925 @entity36705
Diagnosis of @entity3620 ( @entity2615 ) is limited. Novel proteomic techno_logies can be utilized to discover changes in expression of pleural proteins that might have diagnostic value. The objective of this study was to detect protein profiles that could be used to identify @entity3620 with @entity66 ( @entity66 ) mass spectrometry (MS). Pleural effusions were collected from @entity1 with confirmed @entity2615 (n = 41) and from @entity1 with effusions due to other causes ([n = 48] cancerous and non-cancerous). Samples were fractionated using anion exchange chromatography and bound to different types of ProteinChip array surfaces. All samples were also subjected to other commercially available immunoassays ( @entity1 epididymes protein 4 [ @entity3422 ], @entity1096 [ @entity1096 ], @entity36705 [ @entity36705 ], and the @entity4166 fragment [CYFRA 21-1]). Peak intensity data obtained by @entity66 were subjected to classification algorithms in order to identify potential classifier peaks. A protein peak at m/z 6614 was characterized as @entity45925 . In this setting, the sensitivity and specificity of this potential biomarker was 76 % and 69 %, respectively. The area under the receiver operating characteristic curve (AUC) for @entity45925 was 0.755, thereby outperforming @entity1096 , @entity3422 , and CYFRA 21-1. @entity36705 performed best with an AUC of 0.860 with a sensitivity of 83% and specificity of 74%. Our study validates the use of @entity36705 as a diagnostic marker for @entity2615 and furthermore suggests that @entity45925 levels could be used in the future to discriminate @entity2615 from other causes of exudates.
